ClinicalTrials.gg
CompletedNCT06038656FexerGOSUpdated Mar 13, 2025

Exercise and Galactooligosaccharide Supplementation on Inflammation and Iron Absorption (FexerGOS)

An interventional study of Galactooligosaccharides (GOS) in Resistance Exercise, sponsored by North-West University, South Africa. Completed at 1 site in South Africa. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by North-West University, South Africa · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Inflammation with a site in South Africa — 3 open to participants now, 4 under way, 1 of them phase 3. Inflammation · South Africa.

Enrollment
13th of 13
22 · median 220
Started
2024
with 1 other
No phase
3 of 14
1 open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
North-West University, South Africa

Among the 14 studies in Inflammation with a site in South Africa, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 3 with no phase, and was the 12th registered.

Inflammation

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

Browse Inflammation studies →

Open to participants now

3 of the 14 studies in Inflammation with a site in South Africa are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.

This study: 18 Years to 35 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Inflammation with a site in South Africa, or all of them as a file.
02

Study summary

Iron depletion is common in female athletes depending on the sports discipline. Endurance and resistance exercise can induce inflammation thereby reducing dietary iron absorption. Galacto-oligosaccharides (GOS) improved iron absorption in young healthy women and infants, and improved gut inflammation in iron-supplemented infants. A stable isotope study will be performed to investigate the effect exercise and acute and chronic GOS supplementation on inflammation and iron absorption in female athletes.

Read the detailed description

Iron depletion is common in athletes, particularly in females, reaching prevalence rates up to 70% depending on the sports discipline. As iron is essential for energy production and oxygen transport, a deficiency can impair performance, especially in endurance athletes. Iron deficiency in athletes may be caused by inadequate intake, but reduced iron absorption and increased losses also seem to play a role. Both endurance and resistance exercise at a high intensity, can induce inflammation resulting in a hepcidin response via interleukin-6 (IL-6) regulation. Hepcidin is the master regulator of systemic iron homeostasis, and a recent study in adult males showed that vigorous exercise decreases dietary iron absorption associated with increases in IL-6 and hepcidin. Iron losses induced by exercise have been attributed to several factors, including gastrointestinal bleeding associated with endothelial damage, haematuria, haemolysis, and increased sweating. Galacto-oligosaccharides (GOS) have been shown to acutely enhance iron absorption in young, healthy women. In Kenyan infants with a high infectious disease burden, chronic GOS administration improved iron absorption and mitigated the negative effects of iron supplementation on gut inflammation, likely mediated by its bifidogenic effect. Whether GOS has the potential of improving iron absorption has not been studied in athletes.

The study aims are to determine 1) the effects of a bout of resistance exercise at 70% 1 repetition maximum (RM) on inflammation, hepcidin and iron absorption in female team athletes; and 2) the effect of acute and chronic GOS supplementation on iron absorption in response to the exercise bout.

The trial will entail two series of three iron absorption conditions separated by six weeks of GOS supplementation (10 g/day). The study participants will be 22 female athletes recruited from the North-West University and Potchefstroom area, South Africa. At baseline, the first series of three iron absorption studies will be conducted, all measuring iron absorption from a supplement administered with labelled ferrous fumarate in the following conditions: 1) after a period of rest; 2) three hours after an acute resistance exercise bout; and 3) three hours after an acute resistance exercise bout, co-administered with GOS. Following this, participants will consume GOS daily for 6 weeks, followed by an identical series of iron absorption studies. Markers of systemic and gut inflammation, hepcidin, microflora composition and iron status indicators before and after the GOS intervention will be determined. In addition, erythrocyte iron incorporation will be determined after both series of isotope studies. Furthermore, the kinetics of isotope appearance, inflammatory markers, and hepcidin for 24 hours during each of the six iron absorption studies will be investigated.

The primary hypotheses are that fractional iron absorption from a supplemental dose of ferrous fumarate will be: 1) lower three hours post exercise than post resting period; 2) higher with co-administration of GOS than without, both before and after six-week GOS intervention; and 3) higher after six-week intervention with GOS compared to baseline.

The secondary hypotheses are: 1) acute exercise bout will result in increased inflammatory and hepcidin response before and after intervention with GOS but the intervention may mediate these two responses; 2) chronic GOS intervention will increase relative abundance of Bifidobacterium spp, reduce gut inflammation and improve gut integrity and gut health; 3) chronic GOS intervention will improve iron status.

03

Conditions studied

  • Resistance Exercise

Browse trials for

Keywords

  • Galacto-oligosaccharides
  • female athletes
  • iron absorption
  • inflammation
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female athlete.
  2. Train at least 6 hours per week at moderate to high intensity.
  3. Having low to moderate iron stores.
  4. Willingness to consume the study supplement GOS during the intervention period.
  5. Willingness not to consume daily nutritional supplements containing >20 mg iron and/or pre- or probiotics (excluding food and beverages containing live cultures such as yoghurt, raw milk and cheese) during the study.
  6. Willingness to not take any iron-containing supplements two days before and during the iron absorption study days or vitamin C on the iron absorption study days.

Exclusion criteria

Exclusion Criteria:

  1. \<11 g/dl.
  2. Treated or self-reported chronic disease, malabsorptive or gastrointestinal disorders (e.g. irritable bowel syndrome, functional bloating).
  3. Pregnancy or lactation.
  4. Subjects who cannot be expected to comply with the study protocol.
  5. Difficulty drawing blood due to poor quality veins.
  6. Individuals that have a fear of needles or suffer from vaso-vagal episodes when exposed to blood.
  7. Participants who plan to start or stop the use of before or during study period.
  8. Participants who are lactose intolerant.
  9. Participants who donated blood in the past 4 months or plan to donate during the study period.
  10. Participants who use chronic anti-inflammatory medication such as or non-steroidal anti-inflammatory medication (NSAIDS).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Experimental

    Participants will receive 10 g of GOS daily for 6 weeks. Fractional iron absorption will be determined pre- and post the 6-week intervention from 3 conditions: 1) after a period of rest; 2) three hours after an acute resistance exercise bout without GOS and 3) three hours after an acute resistance exercise bout, co-administered with 10 g GOS.

    Dietary Supplement: Galactooligosaccharides (GOS)

Interventions

  • Dietary supplementGalactooligosaccharides (GOS)

    10 g of GOS provided as 14 g of powder will be consumed after mixing it in water or yoghurt. The absorption study test drinks administered during the 3 test conditions will be comprised as follows: Post rest period - 50 mg of iron as ferrous fumarate (Fefum) supplement, 6 mg 54Fe as Fefum and 300 ml of water with sucrose and lactose. Post exercise bout - 50 mg of iron as Fefum, 6 mg 58Fe as Fefum and 300 ml of water with sucrose and lactose. Post exercise bout co-administered with GOS - 50 mg of iron as Fefum, 6 mg 57Fe as Fefum and 300 ml of water with 10 g GOS.

06

What researchers measure

Primary outcomes

  1. a. Fractional iron absorption (%)

    Fractional iron absorption will be measured at rest and after an exercise bout.

    Time frame: Visit 8 (day 29) and 15 (day 92).

  2. b. Fractional iron absorption (%)

    Fractional iron absorption will be measured after an exercise bout with and without co-administration of GOS.

    Time frame: Visit 8 (day 29) and 15 (day 92).

  3. c. Fractional iron absorption (%)

    Fractional iron absorption will be measured at rest and after an exercise bout before and after a 6-week intervention with GOS.

    Time frame: Visit 8 (day 29) and 15 (day 92).

Secondary outcomes

  1. Interleukin 6 (pg/mL)

    Interleukin 6 (IL-6) will be measured over 24 hours after rest and after exercise as a marker of exercise-induced inflammation.

    Time frame: Visits 2 (day 1), 3 (day 2), 4 (day 8), 5 (day 9), 6 (day 15), 7 (day 16), 9 (day 64), 10 (day 65), 11 (day 71), 12 (day 72), 13 (day 78) and 14 (day 79)

  2. C-reactive protein (mg/L)

    C-reactive protein (CRP) will be measured in plasma to detect the presence of acute inflammation.

    Time frame: Visits 2 (day 1), 4 (day 8), 6 (day 15), 9 (day 64), 11 (day 71) and 13 (day 78).

  3. Alpha-1-acid glycoprotein (g/L)

    Alpha-1-acid glycoprotein (AGP) will be measured in plasma to determine the presence of chronic inflammation.

    Time frame: Visits 2 (day 1), 4 (day 8), 6 (day 15), 9 (day 64), 11 (day 71) and 13 (day 78).

  4. Hepcidin (ng/mL)

    Hepcidin, a major regulator of iron absorption and influenced by exercise-induced inflammation, will be measured in plasma over 24 hours.

    Time frame: Visits 2 (day 1), 3 (day 2), 4 (day 8), 5 (day 9), 6 (day 15), 7 (day 16), 9 (day 64), 10 (day 65), 11 (day 71), 12 (day 72), 13 (day 78) and 14 (day 79)

  5. Lipid mediators (pg/µL )

    The following lipid mediators will be measured over 24 hours in plasma in response to exercise-induced inflammation:17-hydroxydocosahexaenoicacid (17-HDHA); 5-, 8-, 9-, 11-, 12-, 15 and 18- hydroxyeicosapentaenoicacid (HEPE); 5-, 8-, 11-, 12- and 15-hydroxyeicosatetraenoicacid (HETE); prostaglandin (PG) E2 and D2, and resolvin (Rv) D1 and E1).

    Time frame: Visits 2 (day 1), 3 (day 2), 4 (day 8), 5 (day 9), 6 (day 15), 7 (day 16), 9 (day 64), 10 (day 65), 11 (day 71), 12 (day 72), 13 (day 78) and 14 (day 79)

  6. Erythropoietin (mIU/mL)

    Plasma erythropoietin, a marker of erythropoiesis, will be measured before and after period of rest and exercise.

    Time frame: Visits 2 (day 1), 4 (day 8), 6 (day 15), 9 (day 64), 11 (day 71) and 13 (day 78).

  7. Serum iron isotope (%)

    Kinetics of serum iron isotope appearance during a period of rest and post-exercise, before and after intervention with GOS, and with and without co-administration of GOS.

    Time frame: Visits 2 (day 1), 3 (day 2), 4 (day 8), 5 (day 9), 6 (day 15), 7 (day 16), 9 (day 64), 10 (day 65), 11 (day 71), 12 (day 72), 13 (day 78) and 14 (day 79).

  8. Gut microbial composition

    Gut microbiota profile will be assessed at baseline and endpoint.

    Time frame: Visit 8 (day 29) and 15 (day 92).

  9. Faecal short chain fatty acids (µmol/g)

    Concentration of short chain fatty acids - acetate, propionate, isobutyrate, butyrate, formate, isovalerate will be measured in faecal samples before and after the 6-week intervention with GOS.

    Time frame: Visit 8 (day 29) and 15 (day 92).

  10. Faecal pH

    Faecal pH will be measured at baseline and endpoint to determine a response to the GOS intervention.

    Time frame: Visit 8 (day 29) and 15 (day 92).

  11. Faecal calprotectin (µg/g)

    Faecal calprotectin will be measured at baseline and endpoint as a marker of gut inflammation.

    Time frame: Visit 8 (day 29) and 15 (day 92).

  12. Faecal zonulin (ng/mL)

    Faecal zonulin will be measured at baseline and endpoint as a marker of the integrity of the intestinal mucosal barrier.

    Time frame: Visit 8 (day 29) and 15 (day 92).

  13. Intestinal fatty acid-binding protein (pg/mL)

    Intestinal fatty acid-binding protein (I-FABP), a marker of intestinal damage, will be measured in plasma at baseline and endpoint.

    Time frame: Screening, Visits 4 (day 8), 8 (day 29), 9 (day 64), 11 (day 71) and 15 (day 92).

  14. Haemoglobin (g/dL)

    Haemoglobin will be measured in whole blood to determine presence of anaemia and for calculation of fractional iron absorption.

    Time frame: Screening,Visit 8 (day 29), 9 (day 64) and 15 (day 92).

  15. Ferritin (µg/L)

    Ferritin will be measured in plasma to determine the presence of iron deficiency.

    Time frame: Screening, Visits 2 (day 1) and 9 (day 64).

  16. Soluble transferrin receptor (mg/L)

    Soluble transferrin receptor (sTfR) will be measured in plasma to determine the presence of iron deficiency.

    Time frame: Screening, Visits 2 (day 1) and 9 (day 64).

  17. Retinol-binding protein 4 (µmol/L)

    Retinol-binding protein 4 (RBP4) will be measured in plasma as a marker of vitamin A status.

    Time frame: Screening, Visits 2 (day 1) and 9 (day 64).

  18. Thyroglobulin (µg/L)

    Thyroglobulin will be measured in plasma as a marker of iodine status.

    Time frame: Screening, Visits 2 (day 1) and 9 (day 64).

  19. Fibroblast growth factor 21 (pg/mL)

    Fibroblast growth factor 21 (FGF-21) will be measured in plasma as a marker of environmental enteric dysfunction (EED).

    Time frame: Screening,Visits 2 (day 1) and 9 (day 64).

  20. Insulin-like growth factor 1

    Insulin-like growth factor 1 (IGF-1) will be measured in plasma as on of the markers of environmental enteric dysfunction.

    Time frame: Screening, Visits 2 (day 1) and 9 (day 64).

  21. Dietary intake

    Dietary intake will be captured using a quantified food frequency questionnaire.

    Time frame: Screening, Visit 8 (day 29) and 15 (day 92).

  22. Method comparison in the measurement of RBP4 (µmol/L)

    Two methods will be compared in the measurement of RBP4 (µmol/L).

    Time frame: Screening

  23. Method comparison in the measurement of Ferritin (µg/L)

    Two methods will be compared in the measurement of Ferritin (µg/L).

    Time frame: Screening

  24. Method comparison in the measurement of sTfR (mg/L)

    Two methods will be compared in the measurement of sTfR (mg/L).

    Time frame: Screening

  25. Method comparison in the measurement of CRP (mg/L)

    Two methods will be compared in the measurement of CRP (mg/L).

    Time frame: Screening

  26. Method comparison in the measurement of AGP (g/L)

    Two methods will be compared in the measurement of AGP (g/L).

    Time frame: Screening

  27. Method comparison in the measurement of I-FABP (pg/mL)

    Two methods will be compared in the measurement of I-FABP (pg/mL).

    Time frame: Screening

  28. Method comparison in the measurement of Thyroglobulin (µg/L)

    Two methods will be compared in the measurement of Thyroglobulin (µg/L).

    Time frame: Screening

07

Study locations

1 site
  • Este Vorster Research Facility
    Potchefstroom, North West 2531, South Africa
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Nov 2024, 8 months.

Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 8 months is below that.

Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Sep 15, 2023
StartActual
Mar 1, 2024
Primary completionActual
Nov 19, 2024
CompletionActual
Nov 25, 2024
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06038656
Lead sponsor
North-West University, South Africa
Responsible party
Linda Malan (Associate Professor, North-West University, South Africa) — Principal investigator
First posted
Sep 15, 2023
Start date
Mar 1, 2024
Primary completion
Nov 19, 2024
Completion
Nov 25, 2024
Last update
Mar 13, 2025

Study contacts

Isabelle Herter-Aeberli
principal investigator · ETH Zurich
Jesslee du Plessis
principal investigator · North-West University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion